Prestige Q1 FY2023 revenue $277.1M, EPS $1.09, reaffirms full-year guidance

Prestige Consumer Healthcare Inc.

2023-Q1 EPS reported $1.09 revenue$277,059,000

Revenue $277.1M, +2.9% YoY; organic revenue (ex-Akorn, FX) declined 1.2%.
Diluted EPS $1.09 vs $1.14 prior year, but ahead of internal expectations.
Net cash from operations $58.2M; Non-GAAP free cash flow $57.2M.
Reaffirmed FY2023 guidance: revenue $1.12-1.13B, EPS $4.18-4.23, FCF >=$260M.
North American OTC flat at $242.5M; International OTC record $34.5M (+28.9%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.